Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples